Daniel de la Iglesia1, Bartu Avci2, Mariia Kiriukova3, Nikola Panic4,5, Maryana Bozhychko6, Vasile Sandru7, Enrique de-Madaria6, Gabriele Capurso8. 1. Department of Gastroenterology, University Hospital of Santiago de Compostela, Santiago de Compostela, Spain. 2. Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey. 3. Department of Upper Gastrointestinal, Pancreatic, and Biliary Diseases, Moscow Clinical Scientific Center, Moscow, Russia. 4. Digestive Endoscopy Department, University Clinic 'Dr Dragisa Misovic-Dedinje', Belgrade, Serbia. 5. School of Medicine, University of Belgrade, Belgrade, Serbia. 6. Gastroenterology Department, Alicante University General Hospital, Alicante, Spain. 7. Gastroenterology and Interventional Endoscopy Department, Clinical Emergency Hospital Bucharest, Bucharest, Romania. 8. Pancreato-Biliary Endoscopy and Endosonography Division, IRCCS San Raffaele Scientific Institute, Milan, Italy.
Abstract
BACKGROUND: Pancreatic cancer is the fourth leading cause of cancer mortality. Most patients are diagnosed with advanced pancreatic cancer, either at locally advanced or metastatic stages, and have a high rate of malnutrition and weight loss which are associated with poor outcomes. Pancreatic exocrine insufficiency is one of the causes of malnutrition and weight loss in these patients. The prevalence and clinical consequences of pancreatic exocrine insufficiency in advanced pancreatic cancer are poorly investigated with heterogeneous results. We sought to determine the prevalence and clinical consequences of pancreatic exocrine insufficiency and the effect of pancreatic enzyme replacement therapy in patients with advanced pancreatic cancer by systematic review and meta-analysis. METHODS: Scopus, Medline, and Embase were searched for cohort studies or randomised clinical trials reporting pancreatic exocrine insufficiency and/or the effect of pancreatic enzyme replacement therapy in patients with advanced pancreatic cancer. We considered pancreatic exocrine insufficiency as an abnormal result on direct and/or indirect pancreatic exocrine function tests. Pancreatic enzyme replacement therapy was evaluated by its effect on survival and quality of life in patients with advanced pancreatic cancer. RESULTS: A total of 11 studies were included; seven studies reported the prevalence of pancreatic exocrine insufficiency and seven the effect of pancreatic enzyme replacement therapy in advanced pancreatic cancer. The pooled prevalence of pancreatic exocrine insufficiency in advanced pancreatic cancer was 72% (95% confidence interval: 55-86%), being significantly higher when tumours were located in the pancreatic head (relative risk = 3.36, 1.07-10.54; p = 0.04) six studies investigated the impact of pancreatic enzyme replacement therapy on survival/quality of life. Pancreatic enzyme replacement therapy was associated with 3.8 months (95% confidence interval: 1.37-6.19) survival benefit. Patients receiving pancreatic enzyme replacement therapy had a trend towards a better quality of life.Conclusions The prevalence of pancreatic exocrine insufficiency in advanced pancreatic cancer is substantial and its treatment can improve the outcomes of these patients.
BACKGROUND:Pancreatic cancer is the fourth leading cause of cancermortality. Most patients are diagnosed with advanced pancreatic cancer, either at locally advanced or metastatic stages, and have a high rate of malnutrition and weight loss which are associated with poor outcomes. Pancreatic exocrine insufficiency is one of the causes of malnutrition and weight loss in these patients. The prevalence and clinical consequences of pancreatic exocrine insufficiency in advanced pancreatic cancer are poorly investigated with heterogeneous results. We sought to determine the prevalence and clinical consequences of pancreatic exocrine insufficiency and the effect of pancreatic enzyme replacement therapy in patients with advanced pancreatic cancer by systematic review and meta-analysis. METHODS: Scopus, Medline, and Embase were searched for cohort studies or randomised clinical trials reporting pancreatic exocrine insufficiency and/or the effect of pancreatic enzyme replacement therapy in patients with advanced pancreatic cancer. We considered pancreatic exocrine insufficiency as an abnormal result on direct and/or indirect pancreatic exocrine function tests. Pancreatic enzyme replacement therapy was evaluated by its effect on survival and quality of life in patients with advanced pancreatic cancer. RESULTS: A total of 11 studies were included; seven studies reported the prevalence of pancreatic exocrine insufficiency and seven the effect of pancreatic enzyme replacement therapy in advanced pancreatic cancer. The pooled prevalence of pancreatic exocrine insufficiency in advanced pancreatic cancer was 72% (95% confidence interval: 55-86%), being significantly higher when tumours were located in the pancreatic head (relative risk = 3.36, 1.07-10.54; p = 0.04) six studies investigated the impact of pancreatic enzyme replacement therapy on survival/quality of life. Pancreatic enzyme replacement therapy was associated with 3.8 months (95% confidence interval: 1.37-6.19) survival benefit. Patients receiving pancreatic enzyme replacement therapy had a trend towards a better quality of life.Conclusions The prevalence of pancreatic exocrine insufficiency in advanced pancreatic cancer is substantial and its treatment can improve the outcomes of these patients.
Authors: Jill E Witvliet-van Nierop; Nicolette J Wierdsma; Karen Ottens-Oussoren; Martijn R Meijerink; Gerd Bouma; Geert Kazemier; Marian A E de van der Schueren Journal: Pancreas Date: 2018-04 Impact factor: 3.327
Authors: Dorine S J Tseng; I Quintus Molenaar; Marc G Besselink; Casper H van Eijck; Inne H Borel Rinkes; Hjalmar C van Santvoort Journal: Pancreas Date: 2016-03 Impact factor: 3.327
Authors: Seong Hyeon Kim; Song Mi Lee; Hei Cheul Jeung; Ik Jae Lee; Joon Seong Park; Mina Song; Dong Ki Lee; Seung-Min Lee Journal: Nutrients Date: 2019-05-22 Impact factor: 5.717
Authors: Patrick Naumann; Jonathan Eberlein; Benjamin Farnia; Jakob Liermann; Thilo Hackert; Jürgen Debus; Stephanie E Combs Journal: Cancers (Basel) Date: 2019-10-26 Impact factor: 6.639
Authors: Agnieszka Lemanska; Colm Andrews; Louis Fisher; Ben Butler-Cole; Amir Mehrkar; Keith J Roberts; Ben Goldacre; Alex J Walker; Brian MacKenna Journal: medRxiv Date: 2022-08-31
Authors: Lumír Kunovský; Petr Dítě; Petr Jabandžiev; Michal Eid; Karolina Poredská; Jitka Vaculová; Dana Sochorová; Pavel Janeček; Pavla Tesaříková; Martin Blaho; Jan Trna; Jan Hlavsa; Zdeněk Kala Journal: J Clin Med Date: 2021-12-10 Impact factor: 4.241